Opus Genetics (IRD) Non-Current Assets (2010 - 2026)
Opus Genetics (IRD) reported Non-Current Assets of $186000.0 for Q1 2026, down 22.18% year-over-year from $239000.0 in Q1 2025, and down 6.53% on a QoQ basis from $199000.0 in Q4 2025.
Opus Genetics (IRD) has 17 years of Non-Current Assets data on file, last reported at $186000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 22.18% year-over-year to $186000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $823000.0 (up 67.62% YoY) and the FY2025 annual result came in at $199000.0, down 21.03% from the prior year.
- Non-Current Assets slipped to $186000.0 in Q1 2026 per IRD's latest filing, from $199000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $252000.0 in Q4 2024 and bottomed at $3000.0 in Q3 2023.
- The 5-year median for Non-Current Assets is $9000.0 (2022), against an average of $104307.7.
- The widest annual swing landed in 2023, when Non-Current Assets sank 57.14%; it then dropped 21.03% in 2025.
- Tracing IRD's Non-Current Assets over 5 years: stood at $6000.0 in 2022, then tumbled by 50.0% to $3000.0 in 2023, then surged by 8300.0% to $252000.0 in 2024, then dropped by 21.03% to $199000.0 in 2025, then slipped by 6.53% to $186000.0 in 2026.
- Per Business Quant, the three latest IRD Non-Current Assets figures stand at $186000.0 (Q1 2026), $199000.0 (Q4 2025), and $212000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | 186,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186,000.00 |
| Dec 31, 2025 | 199,000.00 |
| Sep 30, 2025 | 212,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Dec 31, 2024 | 252,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Mar 31, 2023 | 5,000.00 |
| Dec 31, 2022 | 6,000.00 |
| Sep 30, 2022 | 7,000.00 |
| Jun 30, 2022 | 8,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | 10,000.00 |
| Sep 30, 2021 | 11,000.00 |
| Jun 30, 2021 | 12,000.00 |
| Mar 31, 2021 | 13,000.00 |
| Dec 31, 2020 | 14,000.00 |
| Sep 30, 2020 | 180,564.00 |
| Jun 30, 2020 | 222,470.00 |
| Mar 31, 2020 | 264,066.00 |
| Dec 31, 2019 | 22,000.00 |
| Sep 30, 2019 | 344,919.00 |
| Jun 30, 2019 | 384,024.00 |
| Mar 31, 2019 | 432,908.00 |
| Dec 31, 2018 | 143,258.00 |
| Sep 30, 2018 | 154,265.00 |
| Jun 30, 2018 | 128,550.00 |
| Mar 31, 2018 | 140,165.00 |
| Dec 31, 2017 | 152,245.00 |
| Sep 30, 2017 | 109,841.00 |
| Jun 30, 2017 | 117,395.00 |
| Mar 31, 2017 | 114,473.00 |
| Dec 31, 2016 | 119,435.00 |
| Sep 30, 2016 | 127,825.00 |
| Jun 30, 2016 | 136,143.00 |
| Mar 31, 2016 | 142,120.00 |
| Dec 31, 2015 | 143,685.00 |
| Sep 30, 2015 | 141,438.00 |
| Jun 30, 2015 | 108,626.00 |
| Mar 31, 2015 | 105,547.00 |
| Dec 31, 2014 | 103,777.00 |
| Sep 30, 2014 | 110,408.00 |
| Jun 30, 2014 | 138,868.00 |
| Mar 31, 2014 | 223,429.00 |
| Dec 31, 2013 | 261,302.00 |
| Sep 30, 2013 | 579,598.00 |
| Jun 30, 2013 | 604,093.00 |
| Mar 31, 2013 | 1.00 Mn |
| Dec 31, 2012 | 1.14 Mn |
| Sep 30, 2012 | 279,552.00 |
| Jun 30, 2012 | 836,991.00 |
| Mar 31, 2012 | 1.36 Mn |
| Dec 31, 2011 | 1.53 Mn |
| Sep 30, 2011 | 3.04 Mn |
| Jun 30, 2011 | 3.28 Mn |
| Dec 31, 2010 | 544,140.00 |